Download Protocol version 20070627 IW/JK/PS Testing of Resistance

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Infection wikipedia , lookup

Neonatal infection wikipedia , lookup

Antimicrobial peptides wikipedia , lookup

Human cytomegalovirus wikipedia , lookup

Sarcocystis wikipedia , lookup

Carbapenem-resistant enterobacteriaceae wikipedia , lookup

Infection control wikipedia , lookup

Hospital-acquired infection wikipedia , lookup

Transcript
Protocol version 20070627 IW/JK/PS
Testing of Resistance in relation to Infection control and Antibiotic use in the
Netherlands, Getting Less problems by working together (TRIANGLE)
Project coordinator:
Ina Willemsen
Laboratory for Microbiology and Infection Control
Amphia hospital
PO Box 90158
4800 RK BREDA
The Netherlands
Tel: +31 76 5955238
Fax: +31 76 5953820
E-mail: [email protected]
TRIANGLE study:
Incidence density and clonality of Highly Resistant Micro-Organisms (HRMO) in
Dutch hospitals and the relation with antimicrobial use and infection control.
Coordinating investigator:
Ina Willemsen
Principal investigators:
Jan Kluytmans
Paul Savelkoul
Investigators:
Gunnar Andriesse (Ziekenhuis Lievensberg Bergen op Zoom)
Anton Buiting (SEZ - Tilburg)
Teysir Halaby (Medisch Spectrum Twente - Enschede)
Lodewijk Spanjaard (AMC - Amsterdam)
Patrick Sturm (Radboud – Nijmegen)
Annet Troelstra (UMCU - Utrecht)
Marc Bonte (UMCU – Utrecht)
Christina Vandenbroucke-Grauls (Vumc en AMC - Amsterdam)
Edou Heddema (Vumc)
Kees Verduin (Maxima Medisch Centrium Veldhoven)
Eric van der Vorm (SRDZ - Delft)
Andreas Voss (CWZ - Nijmegen)
Rob Wintermans (Fransiscus Ziekenhuis Roosendaal)
Mireille Wulf (Radboud - Nijmegen en PAMM - Eindhoven)
Jan van Zeijl (MCL – Leeuwarden)
Greet Vos (Erasmus Medisch Centrum – Rotterdam)
Bart Vlaminckx (Antonius ziekenhuis – Nieuwegein)
Bartelt de Jongh (Anonius ziekenhuis – Nieuwegein)
Background:
The increasing emergence and dissemination of HRMO is becoming a world-wide problem in
hospitals (1). This can be caused by a patient carrying a resistant pathogen on admission, by
horizontal transfer between patients, through selection based on antimicrobial use, and by
transfer of resistance genes (2,3,4). The major factors of the development and spread of
HRMO in a hospital are the selective pressure caused by the intensive use of antimicrobial
agents and by breaks in infection control procedures. In 2005 the first definition of highly
resistant micro-organism (HRMO) was published (5,6). In this paper HRMO were defined as
micro-organisms which 1) are known to cause diseases, 2) have acquired an antimicrobial
resistance pattern that hampers empirical therapy, and 3) have the potential to spread. The
designation HRMO is, therefore, dependent on the bacterial species and the antibacterial
agent(s) against which it has acquired resistance.
This definition can be used as a tool for assessing the scale of the resistance problem at a
local, national or international level.
Study objectives:
The primary objective of this study is to determine the variations in the incidence density of
HRMO in Dutch hospitals.
Secondary objectives are to determine the relative importance of clonal spread and spread of
mobile genetic elements and the association between the incidence density of HRMO and
1) the amount of antimicrobial agents used
2) the kind of antimicrobial agents used
3) variations in infection control policies
Methods & Materials:
Design:
Prospective observational multicenter study.
Duration: 2007-2008.
General information on participating hospitals
For the entire hospital and for ICU’s separately: number of admissions, number of patient
days and average length of stay
General data on antimicrobial use:
defined daily doses (DDD) and prescribed daily doses (PDD) for total use, and per group of
antibiotics, according to the ATC/DDD index 2005 from the WHO Collaborating Centre for
Drug statistics Methodology (7). A hospital pharmacist will co-ordinate the data collection.
General data on infection control measures:
Questionnaire on the implementation of infection control procedures including specific
measures for patients with BRMO and general measures. An infection control practitioner will
co-ordinate the study and assists in the local data collection.
Culture & susceptibility methods:
Per hospital the method of susceptibility testing and breakpoints that are used are registered
for relevant bacterial species.
HRMO data and strain collection:
During 2007 and 2008 all HRMO from hospitalised patients are registered and stored at
minus 80 degrees Celsius. For each HRMO the following variables are recorded: patient
information (age, sex, medical speciality, ward), bacterial species, antimicrobial susceptibility
data and source of the isolate. The date of admission and first date of isolation of the HRMO
as well as the date of discharge are registered. Furthermore, it is scored if the patient has
been admitted to the ICU 30 days before the isolation of the HRMO and if bacteraemia with
the HRMO has occurred. Mortality at discharge is scored as well.
From all patients the first available HRMO of each species is stored. When multiple isolates
from one species are found with differences in susceptibility pattern in one patient, only one
is included in the study.
Typing of HRMO
All MRSA strains are stored and typing results from the RIVM are used for primary analysis.
Other HRMO are typed using AFLP (8) or other methods to be agreed upon by the
investigators. To determine the transmission of integrons a PCR amplification of the class 1,
2 and 3 integrase specific intl1 and intl2 genes will be performed on selected strains (9).
Other methods can be used as well after agreement by the investigators.
Definition of nosocomial or ICU-relatedness:
HRMO strains cultured more than 72 hour after admission, or less than 72 hour after
admission but shortly after discharge (within 30 days) are defined as nosocomial HRMO.
Patients who are on an ICU or have been on an ICU, before the isolation of the HRMO, with
a maximum of 30 days, during the same hospitalization are defined as ICU-related. Crosstransmission is defined as genotypically related strains occur in epidemiologically linked
patients. Genetic relatedness was determined on basis of both visual and computerized
interpretation of AFLP patterns. Epidemiological linkage was defined as two patients who
have been in the same hospital location with a maximum time window of 4 weeks. Crosstransmission of integrons is defined as identical integrons that occur in epidemiologically
linked patients. Intraspecies transfer of an integron is defined as two genotypically unrelated
isolates of the same species carrying the same integron. Interspecies transfer of an integron
is defined as two different species carrying the same integron. Intergenus transfer of an
integron is defined as two different genera carrying the same integron.
Data-analyses, quality control & statistics:
Privacy of patients is provided by decoding all data according to the requirements of the
privacy regulation in the Amphia hospital. The data are entered in a database and analysed
using Excel and the Statistical Package for Social Sciences software (SPSS version 12.0).
Statistical significance is accepted when the chance for coincidence was less than 5%.
References:
1. National Nosocomial Infections Surveillance System: National Nosocomial Infections
Surveillance (NNIS) System Report, data summary from January 1992 through June
2004, issued october 2004. Am J. Infect Control 2004. 32:470-485
2.
Paterson D.L. The role of antimicrobial management programs in optimising antibiotic
prescribing within hospitals Clin Inf Dis 2006. 42:S90-5.
3. Austin D.J, Kristinsson K.G, Anderson R.M. The relationship between the volume of
antimicrobial consumption in human communities and the frequency of resistance. Proc.
Natl. Acad. Sci USA 1999. 96:1152-1156
4. Strausbaugh L.J, Siegel J.D, Weinstein R.A. Preventing Transmission of MultidrugResistance Bacteria in Health Care Setting. Clin Inf Dis 2006. 42:828-35
5. Kluytmans-VandenBergh M.F.Q, Kluytmans J.A.J.W, Vos A. Dutch Guideline for
Preventing Nosocomial Transmission of Highly Resistant Micro-organisms (HRMO).
2005. Infection 33(5-6):309-13.
6. WIP guideline, december 2005
7. World Health Organization. 2002. Guidelines for ATC Classification and DDD
assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methology, Norwegian
Institute of Public Health.
8. Savelkoul P.H.M. et al. Amplified-Fragment Lenghth Polymorphism Analysis:the State of an Art.
Journal of clinical Microbiology, 1999. p.3083-3091
9. Koeleman J.G.M, Stoof J. Bijl van der M.W, Vandenbroucke-Grauls C.M.J.E,
Savelkoul P.H.M. Identification of Epidemic Strains of Anicetobacter baumannii by
Integrase Gene PCR. Journal of clinical Microbiology, 2001. p8-13.